


Competent gut care!



Restores an injured intestinal wall!



- Gecse K et al. (2012)
- 2 Chang J et al. (2017)
- 3 Saltzmann ET et al. (2018)
- 4 Leccioli V et al. (2017)
- 5 Nalle SC und Turner JR (2015)
- 6 Morris G et al. (2016)
- 7 Mansueto P et al. (2015) 8 Craig JM (2016) 9 Pietrzak et al. (2017)
- 10 Lee YB et al. (2019)
- 11 Calarge CA et al. (2019) 12 Pavelić Kraljević S et al. (2020)




The connection between an intact intestinal wall and the microbiome has been scientifically proven.

Especially patients with predominant IBS-D (Irritable Bowel Syndrome with diarrhea) often show an increased permeability of the intestinal wall. 13,14,15

Ammonium and heavy metals cause multiple harm to intestinal health:

- promote chronic inflammatory reactions¹⁶
- promote the immigration of pathogenic germs (E. Coli)
- change the intestinal milieu and inhibit the growth of desirable germs (e.g. Bifidobacterium, Lactobacillus)
- can have a negative effect on the viscosity of the mucus¹⁷



PMA zeolite in **PANACEO** MED **DARM-REPAIR** strengthens the intestinal barrier (= tight junctions) and thus **prevents** endotoxemia. This strengthens the intestine, immune system and organs.

¹⁴ Spiller RC et al. (2008) 15 Spiller RC et al. (2000)

¹⁶ Bestalozzi E et al. (2015)




What makes PANACEO DARM-REPAIR unique?

The naturally occurring zeolite clinoptilolite* is optimized through a unique technology called **PMA = Panaceo Micro Activation**

- The PMA zeolite has a particularly high silicon content and thus a very high acid stability
- The specially patented Panaceo Micro Activation technology allows the usable surface area to be extended to the maximum.
- The PMA technology optimizes the selective ion exchange with regard to the promised effectiveness.

PANACEO MED DARM-REPAIR selectively binds harmful substances & releases precious trace elements & minerals

- 18 Pavelić Kraljević S et al. (unpublished 2017)
- * PANACEO obtains zeolite clinoptilolite from an audited and certified mine and further processes the material in Austria with regard to highest quality standards.
- reduction of ammonium within the gastro-intestinal-milieu.
- with a dosage of 3 g PMA zeolite (= approx. 1 serving spoon of powder) the reduction of ammonium was approx. 60 %.¹⁸





Strengthens the intestinal wall¹⁹ and has an anti-inflammatory effect²⁰

Study Design: prospective, controlled randomized double-blind study Inclusion Criteria: adults with mild intestinal wall permeability disorder (zonulin already above cut-off)

Duration: 12 weeks **Number of Patients:** n = 52Dosage: 2 g PMA zeolite (verum, equivalent to 4 capsules MED Darm-Repair) or microcrystalline cellulose (placebo)

Method & Diagnostics: parameters in blood and stool (including zonulin, cytokines, redox biology).


Scientific Lead:

Mag. DDr. Manfred Lamprecht


Leaky-Gut double-blind study

Elevated zonulin and a-1-antitrypsin (A1A) levels are markers of increased intestinal permeability and associated inflammatory responses of a disrupted intestinal barrier.

- After 12 weeks of substitution with PANACEO MED DARM-REPAIR, a positive effect of PMA zeolite was shown in subjects with mild intestinal permeability (biomarker zonulin).
- Strengthening the intestinal wall barrier by decreasing zonulin levels by > 30 % (significant decrease in zonulin; p < 0.05).
- **Tendency of anti-inflammatory effect** (slight increase cytokine IL 10, p < 0.1).



Graph 1: Zonuline-concentration within the stool in the verum or placebo group after 0 and 12 weeks of supplementation, Values are medians ± SD, p < 0.05 (ANOVA), n = 27 (verum), n = 25 (placebo).



Graph 2: a-1-antitypsin in stool (mg/dl) at the beginning of the pilot study (=baseline) and after 12 weeks. The average score was statistically significantly reduced (p = 0.037) within the verum group compared to the placebo group

Study Design: prospective, controlled, double-blind, randomized pilot-study

Inclusion Criteria: Adults suffering from IBS Irritable Bowel Syndrome) with flatulence, diarrhea or obstipation diagnosed through ROM III score

Duration: 12 weeks **Number of Patients:**

41 diagnosed IBS-patients (Irritable Bowel Syndrome)

Dosage: 3 g PMA zeolite orally 2 times a day or micro-crystalline cellulose (control group)

Diagnostics: Symptom load, blood & stool inflammation parameters such as hsCRP, zonulin, a-1-antitrypsin (permeability parameter), interleukin IL-10, and changes in the gut microbiome.

Scientific Lead:

Petkov et.al 2021

Prof. Dr. med Wilhelm Mosgöller

19 Lamprecht et al. (2015) 20 Petkov V et al. (2021)

Pilot study irritable bowel syndrome (IBS)

Results (Graph 2):

- Significant reduction of a-1-antitrypsin (A1A) parameter for inflammations and permeability in the stool) compared to the placebo group (p < 0.037).
- Reduction of high sensitive C reactive protein (hsCRP, inflammation marker in the blood-serum mg/dl).
- Increase of bifidobacterial and lactobacillus types within the gut.



Study Design: NIS (non interventional study) **Inclusion Criteria:**

People diagnosed with IBS (Irritable Bowel Syndrome): flatulence, diarrhea or obstipation and pain

Duration: 8 weeks **Number of Patients:** 200, completed 54

Dosage: 2 x daily, 1 scoop PANACEO MED DARM-

REPAIR orally

Method: ROM III-criteria and

SF-36-questionnaire/comparison

SF-36-questionnaire/comparison "before" the intake and "after" the intake PLUS diaries.

Recruitment: 60 % of patients

from general medical practices, 40 % study call via media. Scientfic Lead: Univ. Prof. Dr. Harald Vogelsang

Graph:

Development of stool consistency of 54 patients during 8 weeks of treatment, daily diary (n = 54). The difference within the improvement is statistically significant.

*Stool-regulation in dual way

21 Vogelsang, unpublished


Table: diary, daily record, statistical evaluation through analysis of variance with measurement repetition, comparison of three periods (beginning, middle, end)

Regulates the stool²¹, especially when suffering from diarrhea and reduces abdominal pain

Preliminary results of the NIS

Results:

- Improvement of stool consistency, when suffering from diarrhea as well as with obstipation*.
- Reduction of pain and flatulence.



Significant improvement of the symptoms after 8 weeks Diary-Documentation (n = 54)		
		Significance/p-Worth
Days with abdominal pain	Continuous Improvement: total	p < 0.001
Days with flatulence	Continuous Improvement: total	p 0.001
Median number of days with bowel movements	Continuous Improvement: total (currently positive trend)	р 0.067
Stool frequency - diarrhea	Too much, becomes less	p 0.039
Stool consistency	To hard, becomes softer To soft, becomes harder	p < 0.001 p < 0.001



Brings liver values back into balance²²

Study Design: Austria-wide plausibility study - liver protection. Pilot study in collaboration with general practitioners, clinics and internists. **Inclusion Criteria:** Patients with elevated liver values

Duration: 2 months Number of Patients: 130 Dosage: 1 serving spoon PANACEO MED DARM-REPAIR 2x daily


Diagnostics: Blood values – GGT,


GOT und GPT

Gut-Liver Axis: increased intestinal permeability has an impact on liver parameters.

Results:

 A significant decrease in liver enzyme levels has been shown in 2/3 of patients, indicating the improvement of liver health.






Graph:

Decrease in liver enzyme values, plot based on median value

Tricalari valdo

22 Oberwinkler et al. (2013 unpublished)



Competent gut care!

MED



- Regulates the stool
- **Reduces** flatulence, abdominal pain and inflammation of the intestine
- Supports the microbiome
- **Strengthens** the intestinal wall & the immune system
- Protects intestines & organs*


Recommended Application: Take one level serving spoon or 3 capsules with a glass of water (100 ml) 2-3 times a day.

Quality Criteria

- Highest Raw Material Quality 9
- **P** Certified Medical Device
- 100 % Natural Ã
- 20 Years of Research
- Independent Gold Standard Studies
- Measurably Higher Effectiveness
- Patented PMA Technology
- Made in Austria

Tips for patients that tend to get obstipation:

- Doctors recommend to start with half of the dosage within the first week.
- If obstipation occurs: immediately reduce dose and support the gut mobility with increased water intake as well as other substances.
- Intake of medication within a time difference of 2 hours.



Panaceo International GmbH

Finkensteiner Straße 5 9585 Villach/Gödersdorf

T: +43/4257/290 64

F: +43/4257/290 64-799

E: office@panaceo.com





